Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for Next-Generation ADCs at AACR 2026

AI Briefing

• – Promatix Biosciences showcases its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to expand the tumour-selective target space for ADCs.
• – The platform enables the identification of novel ADC targets with improved tumour selectivity and reduced off-target effects.
• – This advancement is highlighted at AACR 2026, marking a significant step forward in the development of next-generation ADCs.